Authors

Latest:

Will Immunotherapy Become a Standard of Care for Glioblastoma?

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.

David Adelstein, MD

Latest:

Dr. Adelstein on Adjuvant Therapy for Oral Cancer

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

David Albala, MD

Latest:

Dr. Albala on the Advantages of PSMA-PET Imaging in Prostate Cancer

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

David Albala, MD, Crouse Hospital

David Arenberg, MD

Latest:

Dr. Arenberg on Low-Cost Intervention to Improve Tobacco Cessation for Lung Cancer

David Arenberg, MD, associate professor, Department of Internal Medicine at the University of Michigan, discusses preliminary results of a low-cost intervention to improve tobacco cessation practices within a large university health system.

David B. Page, MD

Latest:

Dr. Page on Hormone-Directed Strategies in Triple-Negative Breast Cancer

David B. Page, MD, medical oncologist, Providence Cancer Center, discusses hormone-directed strategies in the treatment of patients with triple-negative breast cancer (TNBC).

David C. Fryefield, MD

Latest:

Developing Alternative Payment Models That Providers and Commercial Payers Support

Although some of the improvement is a result of prevention and screening, advances in technology and in chemotherapy and immunotherapy pharmaceuticals have been major driving forces in the decline in cancer-related death.

David C. Madoff, MD

Latest:

Dr. Madoff on Selecting Patients With HCC Appropriate for Minimally Invasive Therapy

David C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.

David C. Metz, MBBCh

Latest:

Dr. Metz Discusses Using a Multidisciplinary Approach When Treating NETs

David C. Metz, MBBCh, professor of medicine, co-director, GI Physiology laboratory, Hospital of the University of Pennsylvania, discusses using a multidisciplinary approach to treating neuroendocrine tumors (NETs).

David C. Metz, MD

Latest:

Dr. Metz on Increasing Incidence of Neuroendocrine Tumors

David C. Metz, MD, gastroenterologist, University of Pennsylvania School of Medicine, associate chief, Medical Affairs, Division of Gastroenterology, discusses the increasing incidence of neuroendocrine tumors.

David C. Portnoy, MD

Latest:

Dr. Portnoy on the Importance of Driver Mutations in the Treatment of NSCLC

David C. Portnoy, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of driver mutations in the treatment of non–small cell lung cancer (NSCLC).

David Carbone, MD, PhD

Latest:

The Urgency Dilemma: When to Start Treatment Before Biomarker Results

Experts debate the difficult practice of starting treatment before biomarker testing results are available. They acknowledge that in true emergencies—like symptomatic brain metastases or airway obstruction—immediate intervention with radiation is appropriate and can bridge the time needed for test results.

David Cella, PhD

Latest:

Dr. Cella on Patient-Reported Outcomes in a Clinical Setting

Dr. David Cella from Northwestern University Feinberg School of Medicine on Patient-Reported Outcomes in a Clinical Setting

David Cibula, MD

Latest:

Dr. Cibula on Adding Dendritic Cell-Based Immunotherapy to Chemotherapy in Ovarian Cancer

David Cibula, MD, a gynecologic oncologist at the Gynaecologic Center of Charles University, discusses a trial that examined the addition of dendritic cell-based immunotherapy to chemotherapy in patients with relapsed ovarian cancer.

David D. Chang, MD, PhD

Latest:

Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer

David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.

David D. Thiel, MD

Latest:

Dr. Thiel on Protecting Patients and Providers From COVID-19

David D. Thiel, MD, chair, discusses the measures that are being taken to protect patients and providers from the coronavirus disease 2019 (COVID-19).

David Delaney, MD

Latest:

Big Data Era Arrives in Clinical Practice Via CancerLinQ Project

This new approach—with a focus on personalized, data-driven decisions—is remaking healthcare, and more specifically, changing how oncologists treat cancer.

David E. Avigan, MD

Latest:

Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma

David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.

David Eagle, MD

Latest:

Dr. David Eagle on Cost-Drivers in Oncology

David Eagle, MD, past president of the Community Oncology Alliance (COA) and partner in Lake Norman Oncology, Mooresville, North Carolina, discuss controlling costs of cancer treatment.

David F. McDermott, MD

Latest:

Dr McDermott on the Eligibility Criteria of the LITESPARK-024 Trial in RCC

David F. McDermott, MD, discusses the ongoing, randomized, phase 1/2 LITESPARK-024 trial in patients with advanced renal cell carcinoma, highlighting the eligibility criteria for this clinical trial.